Prospect of ASO-based therapeutics for genodermatoses is also supported by a clinical trial (Phase I/II) of QR-313 for dystrophic epidermolysis bullosa due to mutations of the COL7A1 gene (55). The gene discussed is COL7A1; the disease is Dystrophic epidermolysis bullosa.